image for Understanding the SEC Form S-1 Filing Process for Going Public

Understanding the SEC Form S-1 Filing Process for Going Public

January 10, 2025 | Investor Relations, Investors, IPO, Strategy,

As your company prepares to transition to public markets, understanding the SEC Form S-1 filing process is essential to ensure a smooth and successful IPO. This blog post highlights key considerations for confidential filings and outlines a strategic timeline for a mid-May 2025 offering.


Advantages of Confidential Filing in the SEC Form S-1 Filing Process:
Following the SEC’s rule change in 2017, all private companies are now allowed to file Form S-1 confidentially, which presents several strategic benefits. This approach empowers management to maintain control over the IPO process while reducing market exposure. A confidential filing allows your company to engage privately with institutional investors, receive feedback from the SEC without public scrutiny, and retain strategic flexibility concerning timing and execution.


Strategic Benefits:

  1. “Testing the Water”
    Executive teams can hold preliminary discussions with institutional investors while keeping these conversations confidential. This approach allows them to gain valuable market feedback without making a public commitment. To support these efforts, understanding 13F filings can help your team gain insight into investor positions and priorities.
  2. Regulatory Dialogue
    Your company can privately address comments from the SEC and refine its disclosures, leading to a more polished public filing. Consider Hiring an Outside Writer for Your S-1 to ensure clarity, compliance, and consistent messaging.
  3. Information Control
    Critical business and financial information can remain private until the company decides to proceed, providing a significant competitive advantage. These advantages underscore the importance of using a confidential approach within the SEC Form S-1 filing process, giving your company flexibility while managing risk.

Transition to Public Filing
The transition from confidential to public status is a pivotal moment in the SEC Form S-1 filing process. It requires careful consideration of timing and communication strategy. For a more technical overview of the IPO process and regulatory considerations, you can refer to Harvard Law’s guide to the U.S. IPO process—a helpful supplement for legal teams and compliance officers. Your company must

  • File public documents minimum 15 days before roadshow initiation
  • Implement strict communication protocols to maintain SEC compliance
  • Establish clear spokesperson designation and media response procedures
  • Develop comprehensive communication strategies to prevent potential SEC violations

To avoid potential pitfalls during this stage, ensure all insiders understand trading restrictions—our Insider Trading Basics article can help your team stay compliant.

For a deeper look into timing and disclosure strategy, read our guide on What Happens When Your S-1 Flips to Public from Confidential.


Proposed Timeline for May 2025 IPO:


Critical Success Factors:
Careful planning throughout the SEC Form S-1 filing process is essential to ensure compliance, market confidence, and IPO readiness. Your company’s successful transition to public markets requires careful attention to regulatory compliance, stakeholder communication, and market timing. Engaging experienced advisors early in the process can help navigate complex regulatory requirements while maintaining strategic flexibility throughout the IPO process.

As you plan your journey toward the public markets, work closely with your strategic advisors and IR team. A comprehensive strategy that balances company objectives with tactical execution before, during, and after the offering is key to long-term success. Consider your investor engagement beyond the IPO as well—our Tips for Planning a Successful Investor Day can help you build lasting relationships with the Street.

Gilmartin Group supports companies at every stage of the SEC Form S-1 filing process, from confidential filing to post-IPO communications. Gilmartin Group partners with healthcare and life sciences companies at every step of the IPO process, providing expert guidance and support to ensure a success. To find out more about how we partner with our clients, please contact our team today.


Authored by: Greg Chodaczek, Managing Director, Gilmartin Group

« Back